149 related articles for article (PubMed ID: 36617366)
21. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
23. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of population D-optimal designs via pharmacokinetic simulations.
Hooker AC; Foracchia M; Dodds MG; Vicini P
Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study.
Mak WY; Ooi QX; Cruz CV; Looi I; Yuen KH; Standing JF
Br J Clin Pharmacol; 2023 Jan; 89(1):330-339. PubMed ID: 35976674
[TBL] [Abstract][Full Text] [Related]
26. Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT.
Grudzinski JJ; Floberg JM; Mudd SR; Jeffery JJ; Peterson ET; Nomura A; Burnette RR; Tomé WA; Weichert JP; Jeraj R
Phys Med Biol; 2012 Mar; 57(6):1641-57. PubMed ID: 22398155
[TBL] [Abstract][Full Text] [Related]
27. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.
Ribbing J; Jonsson EN
J Pharmacokinet Pharmacodyn; 2004 Apr; 31(2):109-34. PubMed ID: 15379381
[TBL] [Abstract][Full Text] [Related]
28. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
Hashimoto Y; Sheiner LB
J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
[TBL] [Abstract][Full Text] [Related]
29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
30. Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact.
Xu XS; Yuan M; Karlsson MO; Dunne A; Nandy P; Vermeulen A
AAPS J; 2012 Dec; 14(4):927-36. PubMed ID: 22993107
[TBL] [Abstract][Full Text] [Related]
31. Contribution of Trough Concentration Data in the Evaluation of Multiple-Dose Pharmacokinetics for Drugs with Delayed Distributional Equilibrium and Long Half-Life.
Choi S; Jeon S; Yim DS; Han S
Drug Des Devel Ther; 2020; 14():811-821. PubMed ID: 32158198
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
33. A pharmacokinetic simulation study to assess the performance of a sparse blood sampling approach to quantify early drug exposure.
Sathe AG; Brundage RC; Ivaturi V; Cloyd JC; Chamberlain JM; Elm JJ; Silbergleit R; Kapur J; Coles LD
Clin Transl Sci; 2021 Jul; 14(4):1444-1451. PubMed ID: 33742783
[TBL] [Abstract][Full Text] [Related]
34. Parameter estimation for sigmoid E
Choe S; Lee D
Transl Clin Pharmacol; 2017 Jun; 25(2):74-84. PubMed ID: 32133323
[TBL] [Abstract][Full Text] [Related]
35. Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations.
Tornøe CW; Overgaard RV; Agersø H; Nielsen HA; Madsen H; Jonsson EN
Pharm Res; 2005 Aug; 22(8):1247-58. PubMed ID: 16078134
[TBL] [Abstract][Full Text] [Related]
36. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients.
Cosson VF; Fuseau E
J Pharmacokinet Biopharm; 1999 Apr; 27(2):149-71. PubMed ID: 10567953
[TBL] [Abstract][Full Text] [Related]
37. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
Tod M; Rocchisani JM
J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
[TBL] [Abstract][Full Text] [Related]
38. Performance of different population pharmacokinetic algorithms.
Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
[TBL] [Abstract][Full Text] [Related]
39. A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design.
Davda JP; Dodds MG; Gibbs MA; Wisdom W; Gibbs J
MAbs; 2014; 6(4):1094-102. PubMed ID: 24837591
[TBL] [Abstract][Full Text] [Related]
40. Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models.
Xu XS; Dunne A; Kimko H; Nandy P; Vermeulen A
J Pharmacokinet Pharmacodyn; 2011 Aug; 38(4):423-32. PubMed ID: 21626437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
